Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8860929 | 0.82 | F11 (0.51) | F11CA12CA9POLBAR | |
| SCHEMBL30636806 | 0.81 | CA12 (0.55) | F11CA12CA9POLBAR | |
| SCHEMBL15230239 | 0.81 | CA12 (0.55) | F11CA12CA9POLBAR | |
| SCHEMBL764001 | 0.81 | CA12 (0.59) | F11CA12CA9POLBAR | |
| SCHEMBL27239601 | 0.81 | CA12 (0.55) | F11CA12CA9POLBAR | |
| SCHEMBL19376174 | 0.81 | CA12 (0.55) | F11CA12CA9POLBAR | |
| SCHEMBL16412962 | 0.77 | PPARG (0.57) | F11CA12CA9POLBAR | |
| SCHEMBL9269642 | 0.77 | CA12 (0.54) | F11CA12CA9POLBAR | |
| SCHEMBL30114885 | 0.77 | CA12 (0.54) | F11CA12CA9POLBAR | |
| SCHEMBL19386408 | 0.77 | CA12 (0.54) | F11CA12CA9POLBAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| US-9682972-B2 | 1,2,5-substituted benzimidazoles as flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | disclosed |
| US-9682971-B2 | 1,2,5-Substituted benzimidazoles as flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | disclosed |
| US-20160108028-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-21 | — | — | US | disclosed |
| US-9265770-B2 | 1,2,5-substituted benzimidazoles as FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-23 | — | — | US | disclosed |
| US-20160046600-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | CHAI WENYING (US) | 2016-02-18 | — | — | US | disclosed |
| US-20150246052-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-03 | — | — | US | disclosed |
| US-9067917-B2 | 1,2,5-substituted benzimidazoles as FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| WO-2014151367-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275028-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246052-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | FEN1, FOXM1, CYP3A5 | F11 1010/4885CA12 3099/4885CA9 2201/4885 |
| US-20160046600-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | FEN1, FOXM1, CYP3A5 | F11 1010/4885CA12 3099/4885CA9 2201/4885 |
| US-20140275028-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | FEN1, FOXM1, CYP3A5 | F11 1010/4885CA12 3099/4885CA9 2201/4885 |
| US-20160108028-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | FEN1, FOXM1, CYP3A5 | F11 1010/4885CA12 3099/4885CA9 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.